Neurol. praxi. 2020;21(1):15-18 | DOI: 10.36290/neu.2020.021

Oral pharmacotherapy of dystonia

MUDr. Pavel Filip, Ph.D., doc. MUDr. Marek Baláž, Ph.D.

I. neurologická klinika, Fakultní nemocnice u sv. Anny, Brno

Despite the long history and relatively high use in the clinical practice, oral drugs in the therapy of dystonia are associated with considerable limitations. This review summarizes the options in oral therapy of acute drug-induced dystonia and chronic dystonic syndromes with various drug groups as anticholinergics, antidopaminergic agents, baclofen, benzodiazepines and others. It describes the basic posology, adverse effects and risks, emphasizing the need for individualised approach. In addition to the lacking support in relevant randomized clinical trials, the review underlines the mere symptomatic, non-curative character of the effect and the absence of therapies directly targeting the pathogenesis or disease-modifying drugs, with the exception of a few secondary dystonias.

Keywords: dystonia, oral therapy, acute drug-induced dystonia.

Published: March 30, 2020  Show citation